A Single-Arm Open-Label Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars
Latest Information Update: 26 Sep 2025
At a glance
- Drugs CSB-001 (Primary)
- Indications Corneal disorders
- Focus Adverse reactions
- Sponsors Claris Biotherapeutics
Most Recent Events
- 24 Aug 2025 Planned End Date changed from 31 Aug 2025 to 31 Jan 2026.
- 24 Aug 2025 Planned primary completion date changed from 31 May 2025 to 31 Dec 2025.
- 11 Feb 2025 Planned End Date changed from 28 Feb 2025 to 31 Aug 2025.